Best Options Strategy for QURE
Looking for the best options strategy for uniQure N.V. (QURE)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live QURE option chain right now, and a simple map from your view on QURE to the strategy that fits it. Model any of them in the calculator before you trade.
About QURE
uniQure N.V. (QURE) is a major company in Biotechnology. Options traders on QURE tend to watch , since these can drive large moves in the share price.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam that specializes in gene therapy treatments for rare and serious genetic diseases. The company's commercial product is HEMGENIX, an approved therapy that enables patients with hemophilia B to produce their own factor IX protein, significantly reducing bleeding risk. Beyond this marketed drug, uniQure maintains a pipeline of investigational gene therapies in early-stage clinical trials. AMT-130 is being studied for Huntington's disease, while AMT-260 targets mesial temporal lobe epilepsy, AMT-162 addresses a form of amyotrophic lateral sclerosis caused by SOD-1 mutations, and AMT-191 is being developed for Fabry disease. The company also has partnerships that expand its reach, including a licensing arrangement with Apic Bio for an intrathecally administered ALS therapy and a supply agreement with CSL Behring.
uniQure generates revenue primarily from HEMGENIX sales in the United States market, where hemophilia B patients represent its paying customer base. The company's financial model depends on successfully advancing its pipeline candidates through clinical development, with profitability tied to potential future…
Today's top-scoring strategy for QURE
Our engine ranks defined-risk strategies on the live QURE chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $38 | $1.82 |
| Sell | 1× | PUT | $42 | $3.15 |
| Sell | 1× | CALL | $47 | $5.80 |
| Buy | 1× | CALL | $55 | $3.10 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $59 | −$192 | −$168 | −$155 | −$146 | −$140 |
| $57 | −$146 | −$132 | −$125 | −$122 | −$120 |
| $54 | −$96 | −$94 | −$95 | −$97 | −$99 |
| $52 | −$46 | −$56 | −$65 | −$73 | −$79 |
| $50 | $2 | −$20 | −$37 | −$50 | −$59 |
| $47 | $44 | $12 | −$11 | −$28 | −$40 |
| $45 | $76 | $38 | $11 | −$9 | −$23 |
| $43 | $95 | $57 | $29 | $8 | −$8 |
| $40 | $99 | $67 | $41 | $20 | $4 |
| $38 | $91 | $68 | $47 | $29 | $14 |
| $35 | $74 | $62 | $48 | $34 | $20 |
Live scan from 2026-08-14 · quotes delayed ~15 minutes
Historical backtest: how a Iron Butterfly on QURE would have performed
We approximated a Iron Butterfly on QURE, entered repeatedly over the past year (92 historical entries, each held to expiration) with Black-Scholes-modelled entry premiums. Here is how that would have played out on real QURE price history — an educational backtest, not a prediction of future returns.
Approximate: entry premiums are modelled with Black-Scholes from trailing realised volatility, held to expiration and settled against the real historical close. Real fills, implied volatility and slippage differ — treat it as directional context, not exact returns.
Implied volatility
QURE is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 98% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on QURE currently price in about 98% implied volatility, versus roughly 49% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
QURE's IV Rank is 32/100: implied volatility sits 32% of the way between its 21-day low (89%) and high (116%), and is above 45% of recorded days. Premium is historically cheap, which favours net-debit strategies like long options and debit spreads.
Off that volatility, the options market is pricing a move of about ±$14.14 (±30%) in QURE by 2026-09-18 — a range of roughly $33.13 to $61.41. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, puts and calls on QURE carry a fairly symmetric implied volatility — no strong directional fear is priced in either way.
QURE options chain highlights: open interest, volume and skew
The live QURE options chain shows a put/call open-interest ratio of 0.16 (bullish-leaning (more calls)), with at-the-money implied volatility near 96.5%. Open interest clusters at the $60 call — a common resistance "wall" — and the $36 put, a support "wall": the strikes option writers are most exposed to into expiration.
Snapshot of open interest, volume and implied volatility for the nearest scanned expiration — context, not a trading signal.
QURE insider trading activity (SEC Form 4)
Open-market insider transactions at QURE over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Kapusta Matthew C | Sell | 7,600 | $349K | 2026-07-02 |
| Kapusta Matthew C | Sell | 4,282 | $195K | 2026-07-02 |
| Kapusta Matthew C | Sell | 9,200 | $409K | 2026-07-02 |
| Abi-Saab Walid | Sell | 20,000 | $928K | 2026-06-30 |
| Abi-Saab Walid | Sell | 10,000 | $465K | 2026-06-30 |
| Kaye Jack | Sell | 17,060 | $792K | 2026-06-30 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Liquidity and tradeability
QURE options are reasonably liquid, with bid-ask spreads around 6.1% near the money. Defined-risk spreads and condors are workable; use limit orders and watch the fill on wider multi-leg trades.
Key figures
- Market cap
- $3.0B
- Beta (vs market)
- 0.94
- 52-week range
- $8.73–$71.50 (61% up the range)
- Short interest
- 15.2% of float · 3.5 days to cover
With 15.2% of QURE's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for QURE
If your view on QURE differs, these also scored well in the latest scan:
How to choose an options strategy for QURE
Start with your outlook on QURE, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while QURE stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open QURE in the free calculator →
Frequently asked questions
What is the best options strategy for QURE?
It depends on your outlook. Bullish traders often use a long call or bull call spread on QURE; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are QURE options liquid enough to trade?
uniQure N.V. (QURE) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade QURE options?
Buying a single QURE call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade QURE or any security. Do your own research.
What does uniQure N.V. do?
uniQure N.V. (QURE) operates in the Biotechnology industry. The "About uniQure N.V." section above gives a fuller picture of what the company does and how it earns money.
Does uniQure N.V. pay a dividend?
We don't show a confirmed dividend yield for uniQure N.V. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
Price trend
Tickers related to QURE
Comparing QURE with similar names can help you choose the best options strategy:
Company information
- Headquarters
- Paasheuvelweg 25, Amsterdam, 1105 BP, Netherlands
- Industry
- Biotechnology
- Employees
- 221
- CEO
- Mr. Matthew Craig Kapusta CPA
- Phone
- 31 20 240 6000
- Website
- www.uniqure.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.